Commentary
Type 2 diabetes contributes to biological processes driving the severity of NAFLD, the primary cause for development of chronic liver diseases. Diagnosis, prevention, and treatment of the development and progression of NAFLD and NASH are important issues.
In this review, H. Kim et al. (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea) discuss the pathogenesis of NAFLD/NASH and NAFLD/NASH-derived hepatocellular carcinoma. They provide insights into “adipose-derived adipokines” and “liver-derived hepatokines” as diagnostic and therapeutic targets from NAFLD to HCC.
